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Background: The formation of contractile myofibrils requires the stepwise onset of expression of muscle specific
proteins. It is likely that elucidation of the expression patterns of muscle-specific sarcomeric proteins is important to
understand muscle disorders originating from defects in contractile sarcomeric proteins.
Methods: We investigated the expression profile of a panel of sarcomeric components with a focus on proteins
associated with a group of congenital disorders. The analyses were performed in cultured human skeletal muscle
cells during myoblast proliferation and myotube development.
Results: Our culture technique resulted in the development of striated myotubes and the expression of adult
isoforms of the sarcomeric proteins, such as fast TnI, fast TnT, adult fast and slow MyHC isoforms and
predominantly skeletal muscle rather than cardiac actin. Many proteins involved in muscle diseases, such as beta
tropomyosin, slow TnI, slow MyBPC and cardiac TnI were readily detected in the initial stages of muscle cell
differentiation, suggesting the possibility of an early role for these proteins as constituent of the developing
contractile apparatus during myofibrillogenesis. This suggests that in disease conditions the mechanisms of
pathogenesis for each of the mutated sarcomeric proteins might be reflected by altered expression patterns, and
disturbed assembly of cytoskeletal, myofibrillar structures and muscle development.
Conclusions: In conclusion, we here confirm that cell cultures of human skeletal muscle are an appropriate tool to
study developmental stages of myofibrillogenesis. The expression of several disease-associated proteins indicates
that they might be a useful model system for studying the pathogenesis of muscle diseases caused by defects in
specific sarcomeric constituents.
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The formation of skeletal muscle cells takes place during
embryogenesis, postnatal growth and repair of postnatal
skeletal muscle. Postnatal growth of muscle and regene-
ration of adult skeletal muscle tissue following injury is
accomplished by activation of quiescent satellite cells
that subsequently proliferate, differentiate and fuse with
each other or pre-existing myofibers to regenerate myo-
fibers thereby regenerating the muscle tissue [1]. For these* Correspondence: homa.tajsharghi@gu.se
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distribution, and reproduction in any mediumcharacteristics of self-renewal, cultured satellite cells can
provide an invaluable insight into the basic mechanisms
of sarcomere expression profile, assembly and myofibril-
logenesis. Although previous studies have revealed some
distinct genetic requirements for embryonic, fetal, postna-
tal and adult regenerative myogenesis, the basic mecha-
nisms are likely to be similar [2,3].
Striated muscle formation is a fundamentally conser-
ved process and requires the highly regulated and orde-
red expression of sarcomeric proteins and their assembly
into the sarcomeric contractile unit [4]. The principle
components of striated muscle sarcomeres include parallel
arrays of actin-containing thin filaments, which overlap
with myosin-containing thick filaments. Striated muscleCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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myosin filaments, which is achieved by accessory proteins
that link the different components and hold them in regis-
ter with each other [5]. In the sarcomere many proteins co-
operate to convert the molecular interactions of actin and
myosin efficiently into mechanical force and movement [4].
A common property of many of the sarcomeric compo-
nents of striated muscle is that they often exist as families
of similar isoforms. These isoforms are developmentally
regulated and differentially expressed in a tissue-specific
manner in cardiac, slow and fast muscle [6,7]. The gene-
ration of distinct protein isoforms within a family can re-
sult predominantly by two mechanisms: the differential
expression of multigene families or the production of mul-
tiple protein variants from a single gene via alternative
splicing. Muscle proteins, which exist as various isoforms
in developing and mature skeletal and cardiac muscles are
functionally unique and exhibit distinct contractile and
physiological properties [8-10].
Although several studies have described that during
myofibrillogenesis, the expression of proteins occurs in
an ordered sequence [4], the sequential onset of the in-
dividual isoforms within a family of sarcomeric proteins
is poorly characterized. Elucidation of the expression pat-
terns of sarcomeric proteins and their distinct isoforms
during myogenesis, is important to better understand their
function, formation and assembly into sarcomeric struc-
ture in normal muscle cells. These data will allow a com-
parison with muscle cells obtained from patients suffering
from one of the increasing number of diseases originating
from genetic defects in these proteins. Congenital myop-
athies, a heterogeneous group of muscle disorders defined
by distinctive morphologic abnormalities in skeletal mus-
cle fibers, are often caused by structural defects in sar-
comeric or cytoskeletal proteins [11]. In addition, distal
arthrogryposis (DA) syndromes, a heterogeneous group of
disorders with congenital contractures mainly of hands
and feet, have recently been associated with mutations in
sarcomeric components including ß-tropomyosin (TPM2)
[12,13], fast troponin T (TNNT3) [14], fast troponin I
(TNNI2) [12,15], embryonic myosin heavy chain (MYH3)
[16,17], prenatal myosin heavy chain (MYH8) [18] and
slow myosin binding protein C (MYBPC1) [19].
In the present study, we characterize the expression
profile of a panel of muscle-specific sarcomeric com-
ponents that are associated with congenital diseases by
combining molecular and morphological techniques on




Five standardized batches of human myoblasts were pro-
vided by MYOSIX through a collaborative program withAssociation Francaise contre les Myopathies (AFM). Ske-
letal muscle cells from donors with no clinical signs of
muscle disease were enzymatically isolated and cultured
as previously described [20,21]. Isolated satellite cells,
frozen in liquid nitrogen in their second passage, were
quickly thawed and plated on chamber slides (Lab-Tek™
II - CC2™, Nalge Nunc International, Naperville, USA)
using Dulbecco’s modified Eagle’s medium (DMEM)
(Biochrom AG, Berlin, Germany), supplemented with 20%
fetal bovine serum (Invitrogen, GIBCO, Auckland, New
Zealand), 100x GlutaMAX (Invitrogen, GIBCO, Paisley,
UK), 10 mg/ml penicillin/streptomycin (Biochrom AG,
Berlin, Germany), 10 μm./ml insulin (Biochrom AG,
Berlin, Germany) and 10 ng/ml fibroblast growth factor
(BD Biosciences, Bedford, MA, USA). The cells were incu-
bated at 37°C in a humidified 5% CO2 atmosphere.
To induce differentiation, cells were replenished at
85%-90% confluence with DMEM medium, supplemen-
ted with 5% horse serum (Invitrogen, GIBCO, Auckland,
New Zealand) and further incubated in this medium for
6 days. The medium was changed three times a week.
RNA isolation, cDNA synthesis, polymerase chain reaction
(PCR) and sequence analysis
Total RNA was isolated from proliferating myoblasts
and differentiated cell cultures and treated with DNase I
using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. The total
RNA concentration was determined by A260 and A280
(A260/A280=1.7-2.0) measurements using a NanoDrop
ND 1000 Spectrophotometer (NanoDrop Technologies,
Wilmington, USA). Synthesis of first-strand complemen-
tary DNA (cDNA) was performed from 400 ng total RNA
using the iScript cDNA Synthesis kit (BioRad Laboratories,
2000 Alfred Nobel Drive Hercules, CA), according to the
manufacturer’s instructions.
The expression of transcripts of a panel of genes encod-
ing skeletal muscle sarcomeric components desmin (DES),
titin (TTN), MyHC isoforms (MYH1, MYH2, MYH3,
MYH4, MYH7 and MYH8), α-skeletal actin (ACTA1) and
α-cardiac actin (ACTC1), tropomyosin isoforms (TPM1,
TPM2 and TPM3), troponin T isoforms (TNNT1, TNNT2
and TNNT3), troponin I isoforms (TNNI1, TNNI2 and
TNNI3), skeletal muscle myosin-binding protein C iso-
forms (MYBPC1, MYBPC2) and cardiac myosin-binding
protein C (MYBPC3) was analyzed by reverse transcrip-
tase polymerase chain reaction (PCR). In addition, the
expression of transcripts of myogenic regulatory factors
(MRFs) myogenic factor 5 (MYF5), myogenic differenti-
ation 1 (MYOD1) and myogenin (MYOG) was analyzed.
The PCR analysis was performed on cDNA in a master
mixture (ReddyMix PCR Master Mix, ABgene House,
Blenheim Road, UK) containing 20 pmol of each pri-
mer. The PCR primers were directed to cDNA sequence
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cation, although the RNA samples were treated with
DNase I. Primer sequences are available on request. PCR
amplifications consisted of an initial preheating step for 5
min at 94°C, followed by a touchdown (TD)-PCR. TD-
PCR analysis was performed by denaturation at 94°C for
30 sec, annealing at 65°C for 30 sec, extension at 72°C for
1 min with a 1°C temperature decrement per cycle during
the first 10 cycles. The subsequent cycles (40 cycles) each
consisted of 94°C for 30 sec, 55°C for 30 sec and 72°C for
1 min. The same PCR amplification reaction was per-
formed for all genes, except for the amplification of
myosin heavy chain isoforms that consisted of an initial
preheating step for 3 min at 94°C, followed by denaturation
at 94°C for 1 min, annealing at 57°C for 1 min and exten-
sion at 72°C for 1 min for 35 cycles. Samples were run in
triplicate. The nucleotide sequence determination was car-
ried out by cycle sequencing using an ABI 3730xl DNA se-
quencer (GATC Biotech AG, Konstanz, Germany).
Immunocytochemistry and immunofluorescence
Immunocytochemical analysis was performed on pro-
liferating myoblasts and myotubes after 6 days of dif-
ferentiation, grown on chamber slides using LSAB kit
(DAKO, Glostrup, Denmark) according to manufactu-
rer’s instructions. The cells were incubated with primary
antibodies (Table 1) followed by incubation with EnVi-
sion™Flex/HRP. The immunoreactivity was visualized by
the indirect peroxidase-antiperoxidase complex method
(DAKO, Glostrup, Denmark) using diaminobenzidine as
a chromogen. Nuclei were counterstained with hemato-
xylin (Novocastra, Leica Microsystems Newcastle Ltd).
Immunoreactivity was analyzed by light microscopy using
the Zeiss Axio Observer microscope (Carl Zeiss AG,
Germany) equipped with 10×, 20× and 40× objectives.
For immunofluorescence assays, slides were washed
three times in 0.01 M phosphate-buffered saline (PBS)
and fixed in 4% formaldehyde (methanol-free 16% for-
maldehyde solution, Thermo scientific) for 10 min. Free
aldehyde groups were blocked with 50 mM NH4Cl for
10 min and cells were permeabilized in 0,01 M PBS con-
taining 0,1% Triton X-100 for 4 min. Cells were incu-
bated with primary antibodies for 1 h in a humidified
chamber at 37°C, followed by incubation with secondary
antibodies for 1 h in the dark and three washes with
0.01 M PBS. Finally, the slides were mounted with a
coverslip using ProlongW Gold antifade reagent with
DAPI (Invitrogen, GIBCO, Auckland, New Zealand) to
highlight cell nuclei. The slides were left overnight in the
dark at room temperature before examinations.
Results
The experiments were conducted in triplicate with simi-
lar results.RNA expression and sequence analysis
The appearance of the myogenic phenotype in the in-
vestigated cell cultures was verified by analyzing the ex-
pression of the genes encoding a family of transcription
factors known as MRFs including MYOD1, MYF5 and
MYOG that are responsible for controlling muscle-spe-
cific gene expression. Expression of all MRFs was rea-
dily detectable in both proliferating mononucleated
myoblasts and cells after 6 days of differentiation (D6)
(Figure 1A and B).
The expression of tropomyosin isoforms TPM1, TPM2,
TPM3, α-skeletal and α-cardiac actin (ACTA1 and
ACTC1), MyHC isoforms (MYH1, MYH2, MYH3, MYH4,
MYH7, MYH8), DES, TTN, slow, fast and cardiac my-
osin-binding protein C isoforms (MYBPC1, MYBPC2,
MYBPC3), troponin I isoforms (TNNI1, TNNI2, TNNI3),
and troponin T isoforms (TNNT1, TNNT2, TNNT3) was
detected in both myoblasts and D6 cells (Figure 1A-H).
In order to confirm and verify the expression of each
specific transcript in both myoblasts and differentiated
cells, a sequence analysis of the amplicons was perfor-
med. Using the NCBI BLAST website http://www.ncbi.
nlm.nih.gov/BLAST/, the 100% identity to the reference
sequences were confirmed for the MRF transcripts (MYOD1,
MYF5 and MYOG), as well as the muscle specific alterna-
tive splicing variant of the investigated sarcomeric trans-
cripts (Additional files 1, 2, 3, Figure S1–S3).
Immunocytochemistry and immunofluorescence
Mononucleated myoblasts were differentiated into mul-
tinucleated cells to induce the development of myotubes
containing cross-striated myofibrils. The mature sarco-
meric cross-striated pattern of the myofibrils within dif-
ferentiated cells was confirmed by immunostaining with
a panel of titin antibodies: all sarcomeric structures
(Z-disk, A/I-junction, A-band and M-band) were clearly
detected after only 5 days of differentiation (Figure 2).
To confirm the myogenic identity of the analyzed cells
they were stained with an antibody against desmin. The
expression of desmin was homogeneous and the anti-
body strongly stained virtually all cells of both proli-
ferating myoblasts (Figure 3A) and differentiated (D6)
cultures (Figure 4A). In order to determine the stage of
differentiation of the mononucleated myoblasts and the
differentiated cells, an antibody against myogenin was
used. Only a small number of the myonuclei of prolifer-
ating mononucleated cells were found to express myo-
genin (Figure 3B), whereas the majority of the nuclei
were myogenin positive in the multinucleated differen-
tiated cells confirming their more advanced differen-
tiation level (Figure 4B).
In order to examine the sequential onset of the expres-
sion of sarcomeric proteins and their isoforms, we per-
formed immunocytochemical analyses on mononucleated
Table 1 Antibodies used for the immunocytochemical and immunofluorescence analyses





Mouse monoclonal to desmin M0760 Desmin 1:100 1:1000 Anti-mouse Dylight 549 DakoCytomation
Mouse monoclonal [F5D] to myogenin Ab1835 Myogenin 1:50 Abcam plc
Mouse monoclonal to troponin T, fast NCL-TROPT TNNT 1:20 NovoCastra™Lyophilized
Mouse monoclonal to titin 3010-S Titin 1:50 BioCytex
Mouse monoclonal to sarcomeric actin M0874 Alpha-skeletal actin 1:10 1:1000 Anti-mouse Dylight 549 DakoCytomation
Mouse monoclonal cardiac actin M622709 Alpha-cardiac actin 1:20 1:1000 Anti-mouse Dylight 549 Nordic Biolabs Bioreagents
Mouse monoclonal to myosin heavy
chain, (developmental)
NCL-MHCd MyHC-embryonic 1:10 1:1000 Anti-mouse Dylight 549 NovoCastra™Lyophilized
Mouse monoclonal to myosin heavy
chain, (neonatal)
NCL-MHCn MyHC-neonatal 1:10 1:1000 Anti-mouse Dylight 549 NovoCastra™Lyophilized
Mouse monoclonal to myosin heavy
chain, (slow)
NCL-MHCs MyHC-slow 1:250 NovoCastra™Lyophilized
Mouse monoclonal to myosin heavy
chain, (fast)
NCL-MHCf MyHC-fast 1:120 NovoCastra™Lyophilized
Mouse monoclonal to myosin heavy
chain, (fast IIa and slow)
N2.261 MyHC-fast IIa+slow 1:120 1:1000 Anti-mouse Dylight 549 Santa Cruz Biotechnology
Mouse monoclonal to sarcomeric tropomyosin T9283 TPM 1:100 Sigma-Aldrich
Rabbit polyclonal to beta tropomyosin ARP48224T100 TPM2 1:120 Aviva Systems Biology
Rabbit polyclonal to myosin binding
protein C, (slow)
HPA021004 MYBPC1-slow 1:50 Sigma-Aldrich
Rabbit polyclonal to myosin binding
protein C, (fast)
SAB2101539 MYBPC2-fast 1:100 Sigma-Aldrich
Mouse monoclonal [12F10] to skeletal
muscle troponin I, (slow)
Ab8293 TNNI-slow 1:500 Abcam plc
Mouse monoclonal [2F12A11] to skeletal
muscle troponin I, (fast)
Ab119943 TNNI- fast 1:200 Abcam plc
Mouse monoclonal [284(19C7)] to cardiac
troponin I
Ab19615 TNNI- cardiac 1:500 Abcam plc
Mouse monoclonal T12 to Z-disk titin Z-disk 1:20 Polyclonal Anti-Mouse
Immunoglobulins/FITC 1:1000
Fürst et al., 1988
Mouse monoclonal T3 to A/I junction titin A/I junction 1:5 Polyclonal Anti-Mouse
Immunoglobulins/FITC 1:1000
Fürst et al., 1988
Mouse monoclonal T30 to A-band titin A-band 1:5 Polyclonal Anti-Mouse
Immunoglobulins/FITC 1:1000
Fürst et al., 1989
Mouse monoclonal T51 to M-band titin M-band 1:5 Polyclonal Anti-Mouse
Immunoglobulins/FITC 1:1000





















Figure 1 RT-PCR analysis of myogenic regulatory factors (MRFs) and a panel of striated muscle sarcomeric genes in myoblasts and
cells differentiated for 6 days. RNA isolated from proliferating mononucleated myoblasts (A, C, E and G) and cultures after 6 days of
differentiation (B, D, F and H) was analyzed by RT-PCR and the products were separated on agarose gels. The expression of MRF genes
(MYOD1, MYF5 and MYOG), TM isoforms, ACTA1, ACTC1, different MyHC isoforms, DES, TTN and MyBPC isoforms, and troponin I and T isoforms
was readily detectable in myoblasts and differentiated cells.
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antibodies (Table 1). While the expression of titin was
observed in a subset of myoblasts (Figure 2A-D and 3C),
this protein was expressed and organized into a cross-
striated pattern in differentiated cells (Figure 2E-H and
4C). The expression analysis of various MyHC isoforms
was performed using five different MyHC antibodies. Al-
though MyHC isoforms were predominantly detected in
differentiated cells, about 10% of mononucleated myo-
blasts also expressed embryonic, neonatal, slow and fast
MyHC (Figure 3D-H, insets). The vast majority of multi-
nucleated myotubes stained strongly with the antibody
against embryonic MyHC (Figure 4D-H). The expression
pattern of slow and fast MyBPC was studied using two
specific antibodies. While virtually all proliferating mono-
nucleated and differentiated cells appeared to be stained
with the antibody against slow MyBPC, these cells were
weakly stained with the antibody against fast MyBPC
(Figure 3I-J and 4I-J). In addition, no specific staining of
proliferating mononucleated myoblasts or multinucleated
differentiated cells with cardiac-specific MyBPC antibody
was detected (data not shown).
Immunohistochemical analysis with alpha-cardiac and
alpha-skeletal actin antibodies revealed uniform stainingof proliferating myoblasts (Figure 3K and L). While strong
expression of alpha-cardiac actin was detected in the myo-
blasts (Figure 3K), these cells appeared weakly stained by
the alpha-skeletal actin antibody (Figure 3L). In contrast,
in multinucleated differentiated cells the intensity of stain-
ing for alpha-skeletal actin appeared to be much stronger
than for alpha-cardiac actin (Figure 4K and L).
The expression of tropomyosin isoforms was studied
in both myoblasts and differentiated cells using two differ-
ent antibodies. The monoclonal anti-sarcomeric tropo-
myosin antibody detects all three TM isoforms (α-, β- and
γ-TM isofoms), whereas the TPM2 antibody is specific for
the β-TM isoform. Although both antibodies produced
uniform staining of proliferating mononucleated cells
(Figure 5A and B), the intensity of staining of multi-
nucleated cells appeared to be much stronger (Figure 5C
and D). While expression of the fast TnT isoform was un-
detectable in proliferating myoblasts, strong expression
was detected in multinucleated cells (Figure 5E and F). To
assess the expression of TnI isoforms, specific anti-slow
and anti-fast troponin I antibodies were used. Expression
of slow TnI isoforms was detected in both mononucleated
and multinucleated differentiated cells (Figure 5G and H),
whereas the fast TnI isoform was solely expressed in
Figure 2 Immunofluorescence micrographs of stained myoblasts and 5-day myotube cultures. Staining with monoclonal antibodies
recognizing titin epitopes in the Z-disk (A and E), A/I junction (B and F), A-band (C and G) and M-band (D and H) reveal development of mature
cross-striated myofibrils. Nuclei were stained with DAPI (blue). The bars represent 10 μm.
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multinucleated myotubes formed myofibre-like cells
with peripheral nuclei (Figure 5H and J; arrows). Immuno-
cytochemical analyses of cardiac TnI confirmed a uni-
form staining of proliferating mononucleated myoblasts
(Figure 5K) and a vast majority of myotubes (Figure 5L).
Immunofluorescence analysis confirmed these results
(Additional file 4: Figure S4).
Supplemental information
Supplemental Appendix includes four figures.
Discussion
Skeletal muscle myoblasts are capable of proliferation
and differentiation in vitro, which imitates early embryo-
nic development and muscle regeneration. In several
studies mammalian or avian cultured myocytes have
been used as an experimental model to analyze the tem-
poral and spatial expression of myofibrillar proteins dur-
ing myogenesis in cardiac and skeletal muscles [1,4,22-25].
These studies have lead to the understanding that during
myofibrillogenesis, the initiation of the expression of themany proteins involved occurs in an ordered sequence,
suggesting a specific impact of the individual proteins in
the complex mechanisms associated with sarcomere for-
mation [4]. Due to their limited availability and reduced
level of differentiation, human cells were only used in few
studies. A better knowledge of their expression patterns
and contribution to the assembly of cytoskeletal and myo-
fibrillar structures in human cells might provide insights
into the pathomechanisms of diseases associated with
mutations in genes encoding sarcomeric proteins. In the
current study we have used cultured primary human skel-
etal muscle cells to investigate the expression patterns of a
panel of sarcomeric components and their isoforms with a
focus on proteins associated with a group of muscle dis-
eases. It is of interest to understand the onset of the ex-
pression of such proteins related to the congenital feature
of the disease. Our differentiated cultures were predomin-
antly occupied by myotubes, showing a mature sarcomeric
cross-striated pattern. We observed a subsequent expres-
sion and development stages of myofibril components
from an initial unorganized pattern in myoblasts, into a
mature cross-striated pattern with clearly distinguishable
Figure 3 Immunocytochemical analysis of proliferating human mononucleated myoblasts. (A) The strong homogeneous staining for
desmin revealed the myogenic potential of virtually all mononucleated cells. (B) Only a small number of the myonuclei of proliferating cells
expressed myogenin (arrows). (C) A subset of myoblasts showed immunoreactivity with antibody against titin. (D-E-F-G-H) Demonstrate positive
staining of a few cells with antibodies against MyHC-embryonic, MyHC-neonatal, MyHC-slow/beta cardiac, MyHC-fast and MyHC-fast IIa+slow,
respectively. Insets demonstrate considerable numbers of mononucleated myoblasts expressing various MyHC isoforms, as indicated.
Homogeneous staining of proliferating mononucleated cells with antibodies against slow (I) and fast (J) MyBPC respectively. Uniform and strong
staining of proliferating myoblasts with antibody against alpha-cardiac actin (K). The cells were weakly stained with antibody against alpha-
skeletal actin (L). The bar represents 10 μm and 100 μm for the insets.
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pearance of these four well-defined sarcomeric structures,
and in particular, the integration of M-band titin, which is
a late stage in myofibrillogenesis [26], indicated the forma-
tion of mature sarcomeric structures in vitro. This indi-
cates the high quality of our human tissue culture and
confirms its usability as a model system for studying thepathogenesis of muscle diseases caused by defects in sar-
comeric or cytoskeletal constituents during skeletal mus-
cle development.
Our results identify α-cardiac actin and α-skeletal actin
as the predominant actin isoform in mononucleated myo-
blasts and in multinucleated differentiated cells, respecti-
vely demonstrating that the expression of actin isoforms is
Figure 4 Immunocytochemical analysis of human cells after 6 days of differentiation. (A) shows strong homogeneous staining for desmin
of the cells. (B) The differential capacity of the multinucleated cells was demonstrated by myogenin-positive staining of the majority of the nuclei.
(C) Strong homogeneous staining of differentiated cells with an antibody against titin. (D) The vast majority of differentiated cells showed strong
staining with the antibody against MyHC-embryonic and (E) many myotubes expressed neonatal MyHC. (F-H) expression of fast and slow MyHC
was revealed in a subset of fused cells using antibodies against these isoforms. Positive staining of differentiated cells with antibodies against
slow (I) and fast (J) MyBPC, respectively. The differentiated cells showed weak positive immunoreactivity with the antibody against alpha-cardiac
actin (K) but stronger positive staining with alpha-skeletal actin (L). The bar represents 10 μm.
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manner. This is in accordance with previous results in
chicken and mouse (27–29), that revealed that α-cardiac
actin is the main isoform in early skeletal muscle develop-
ment [27,28]. Its expression is down-regulated in later de-
velopment and α-skeletal actin becomes the predominant
isoform in adult skeletal muscle fibres [29].We also show the predominant expression of the β-TM
isoform in proliferating human myoblasts and myotubes
during myogenesis in vitro. This indicates an important
role for β-TM in early stages of myofibrillogenesis. In
addition, our data indicate that myoblasts and early-
differentiated myotubes contain predominantly slow
TnI, suggesting the importance of this isoform during
Figure 5 Immunohistochemical analysis of human myoblasts and cells after 6 days of differentiation. Homogeneous staining of cells with
(A) antibody against three different sarcomeric TM isoforms and (B) a specific antibody against beta-tropomyosin, β-TM isoform. (C) Strong
positive staining of multinucleated cells with an antibody against sarcomeric TM isoforms. (D) Staining of cells with specific antibody against
beta-tropomyosin. (E) The mononucleated cells were negative for fast troponin T expression, while positive immunoreactivity was observed
in (F) multinucleated cells, as illustrated by the anti-fast TNNT MAb staining. Homogeneous staining of (G) proliferating myoblasts and
(H) multinucleated myotubes with antibody against slow isoform of troponin I. No expression of fast troponin I was detected in (I) proliferating
myoblasts whereas positive staining was observed in (J) differentiated cells by an antibody against this isoform. Homogeneous immunoreactivity
of both (K) proliferating myoblasts and (L) multinucleated cells with antibodies against cardiac isoform of troponin I. A subset of the
multinucleated myotubes have a myofibre-like appearance with peripherally located nuclei (H and J; arrows). The bar represents 10 μm.
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notion that the slow troponin I gene is the major isoform
in early fetal heart in vertebrates and it is predominantly
expressed during development in fast muscles with a sub-
sequent switch to fast troponin I [30,31,32]. Similarly, we
detected the expression of fast TnI and T solely in
differentiated myotubes, indicating their impact in laterstages of muscle development. Moreover, in accordance
with previous results [33] the homogeneous expression
of cardiac TnI in proliferating myoblasts and early myo-
tubes suggest a role for this protein in the initial stages
of myofibrillogenesis.
Association of mutations in slow skeletal muscle MyBPC
isoform (MYBPC1) with autosomal dominant DA type 1
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isoform as the major MyBPC variant at the initial phases of
myofibrillogenesis in human skeletal muscle myoblasts and
early myotubes, indicating that it is the main MyBPC iso-
form involved in early myofibril development. Accordingly,
previous results indicate that slow MyBPC is first ex-
pressed in developing skeletal muscle both in mice and
humans and fast MyBPC is detected at later developmental
stages [3]. Also in accordance with a previous study, which
indicated that cardiac MyBPC is not expressed in human
skeletal muscles, not even during development [3], the ex-
pression of this isoform was not detected in our cultures.
This indicates that the cardiac MyBPC appears not to be
essential for human skeletal muscle development. However
the cardiac MyBPC transcript was clearly detected in both,
proliferating mononucleated myoblasts and myotubes, in-
dicating the ectopic expression of this gene, as previously
suggested [34]. In addition, we observed the expression of
muscle-specific sarcomeric transcripts in proliferating
mononucleated myoblasts, which either suggests the exist-
ence of myoblasts that had begun to express these compo-
nents prior to fusion, or an expression of muscle-specific
proteins in mononucleated myoblasts that differentiate
prematurely. We found early expression of various MyHC
protein isoforms, in a population of proliferating mono-
nucleated myoblasts with an elongated spindle-shaped
morphology without fusion. This may indicate the co-
existence of early differentiated but non-fused myoblasts
within the population of proliferating myoblasts in adult
regenerative muscle. In addition, a small number of the
proliferating mononucleated myoblasts expressed myo-
genin, confirming their differentiated state.
The essential roles of sarcomeric proteins have been
highlighted by identification of mutations in their genes
associated with various diseases. This includes muta-
tions in genes encoding β-TM and γ-TM isoforms (TPM2
and TPM3) in association with congenital myopathies
with a range of clinical and morphological phenotypes
[12,13,35-42]. In addition, mutations in TPM2, TNNI2,
MYH3, MYH8 and MYBPC1 have recently been identified
to cause the DA syndromes, characterized by congenital
contractures [12,15]. The sequential onset of distinct sar-
comeric protein isoforms within a family has not been
well-characterized in human, except for the MYH3 and
MYH8, which are known to be expressed during fetal de-
velopment and also during muscle regeneration [43,44].
The impact of embryonic and fetal MyHC isoforms for
normal fetal development was supported by the identifi-
cation of MYH3 and MYH8 mutations [16,17,45] [18,46].
It was suggested that they cause a developmental myopathy
resulting in reduced fetal movement and joint contractures
[16,17]. Our results here demonstrated the predominant
expression of β-TM, cardiac alpha actin, slow TnI and slow
MyBPC isoforms in proliferating human mononucleatedmyoblasts and myotubes during myogenesis in vitro. This
points to a possible role for these protein isoforms in the
early stages of myofibrillogenesis. Mutations in such pro-
teins may affect muscle function during early development
either through haploinsufficiency with insufficient dosage
of a functional protein or a dominant negative effect of the
mutated allele by functional or structural alterations.
Conclusion
In conclusion, we here confirm that cell cultures of hu-
man skeletal muscle are an appropriate tool to study de-
velopmental stages of myofibrillogenesis. We show that
many proteins involved in muscle diseases are readily
detected in the stages of skeletal muscle cell differenti-
ation that can be reached in vitro. The early and uniform
expression of these proteins suggests their impact on the
developmental mechanisms involved in the initial stages
of myofibril assembly, differentiation and formation of
muscle. This indicates that myoblasts isolated from pa-
tients with a mutation in one of the investigated genes
may be an invaluable tool to analyze the effects of these
mutations on sarcomere assembly and disassembly or myo-
fibril turnover. It would provide us new insights into deve-
lopment of muscle to indicate whether these diseases are
disorders of myofibrillogenesis and muscle development.
Additional files
Additional file 1: Figure S1. Sequence analysis of MRF transcripts, TM
isoforms, α-skeletal and α-cardiac actin, desmin and titin in both
proliferating mononucleated myoblasts and cells after 6 days of
differentiation. (A) Sequence chromatograms of part of cDNA of MRFs
(MYOD1, MYF5 and MYOG) genes. (B) Sequence chromatograms of part of
cDNA of different TM isoforms including TPM1, TPM2 and TPM3. (C)
Sequence chromatograms of part of cDNA of α-skeletal and (ACTA1) α-
cardiac (ACTC1) actin. (D) Sequence chromatograms of part of desmin
(DES) and titin (TTN) genes. The accession number and position of each
gene is indicated.
Additional file 2: Figure S2. Sequence analysis of TnT, TnI and MyBPC
isoforms in proliferating mononucleated myoblasts and cells after 6 days
of differentiation. (A) Sequence chromatograms of part of cDNA of slow
skeletal (TNNT1), cardiac (TNNT2) and fast skeletal (TNNT3) muscle
troponin T. (B) Sequence chromatograms of part of cDNA of slow, fast
and cardiac troponin I (TNNI1, TNNI2 and TNNI3). (C) Sequence
chromatograms of part of cDNA of slow and fast skeletal muscle MyBPC
(MYBPC1 and MYBPC2) and cardiac-specific (MYBPC3) isoforms. The
accession number and position of each gene is indicated.
Additional file 3: Figure S3. Sequence analysis of different MyHC
isoforms in proliferating mononucleated myoblasts and cells after 6 days
of differentiation. Sequence chromatograms of a specific region of cDNA
of different MyHC isoforms including MYH1, MYH2, MYH3, MYH4, MYH7
and MYH8. The accession number and position of each isoform is
indicated.
Additional file 4: Figure S4. Immunofluorescence micrographs of
myoblasts and cells after 6 days of differentiation. (Emphasis>/Emphasis>)
Proliferating myoblasts stained with antibodies against desmin, (B)
embryonic MyHC, (C) neonatal MyHC and (D) fast and slow MyHC, (E)
alpha-skeletal actin, (F) all tropomyosin isoforms, (G) beta-tropomyosin
isoform, (H) slow troponin I and (I) cardiac troponin I. Cells after 6 days of
differentiation stained with antibody against (J) desmin, (K) embryonic
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http://www.biomedcentral.com/1471-2474/13/262MyHC, (L) neonatal MyHC and (M) fast and slow MyHC, (N) alpha-skeletal
actin and (O) cardiac troponin I. These staining patterns confirm the data
obtained by immunocytochemistry. Nuclei were stained with DAPI (blue).
The bar represents 10 μm.
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